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Introduction
Globally, cervical cancer is one of the most common
cancers in women, constituting up to 25% of all female
cancers, and is the most common cancer in developing
countries [1]. It kills around 250,000 women every year
worldwide [2] and around 1,000 in Taiwan [3]. Cervical
cancer is largely preventable through screening programs
designed to diagnose cervical lesions that may progress
to invasive cancer. In past decades, this strategy has had
high success rates in some industrialized countries.
However, it has been challenging to establish and
maintain effective screening programs in developing
countries [4]. The primary cause of cervical cancer in
women has recently been definitively linked to genital
human papillomavirus (HPV) infections. HPV fulfills
the criteria for a carcinogenic agent defined by the
International Agency for Research on Cancer [5]. In a
few instances, HPV can also cause cancer of the anal
canal, vulva, penis, and oropharynx.
Prevalence and Incidence of Cervical Cancer
Cervical cancer is the most frequent neoplasm and has
the fifth highest mortality rate of malignancies of women
[6–8]. Approximately 500,000 women worldwide devel-
op cervical cancer yearly, resulting in about 200,000
cervical cancer deaths each year [8]. Cancer of the cervix
has the highest incidence of any cancer in women in
Taiwan [9,10]. To date, around 1,000 women die of
this disease in Taiwan annually. Not only are the costs
of treatment high, but there is also the need for expensive
screening programs for early detection, and for costly
secondary screening via colposcopy. Moreover, the
available forms of treatment, surgery, radiation therapy,
and chemotherapy [11–13], are all cytoreductive, killing
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both cancerous and healthy cells. Indeed, there is a need
to decrease the incidence of cervical cancer and develop
better forms of prevention and screening.
Risk Factors for Cervical Cancer
Early epidemiologic studies have shown that sexual
activity is a risk factor for cervical carcinoma [14], as is
the sexual activity of partners [15]. HPV and chlamydia
infection are also involved in the risk of cervical cancer
[16–18]. Sexual activity and parity before 18 years of
age, smoking, some nutritional deficiencies mainly
related to antioxidant agents, and socioeconomic status
are also important risk factors [19,20]. In fact, cancer
is a multi-etiologic disease, and multiple steps are
probably necessary for cervical carcinogenesis [21].
Human Papillomavirus
HPVs belong to the family Papovaviridae. They are
relatively stable and, because they have no envelope,
remain infectious for months in a moist environment
[22]. Papillomaviruses are widespread among higher
vertebrates but exhibit a strict species specificity;
transmission from non-primates to humans has not
been reported. In general, HPVs cause local epithelial
infections, with the exception of animal fibropapilloma
viruses, where the infection can also be found in the
dermis. Viremia with viral spread to distant sites does
not occur.
The HPV genome consists of 8,000 base pairs, and
is a double-stranded DNA molecule [23]. The relative
arrangement of the 8–10 open reading frames (ORFs)
within the genome is the same in all papillomavirus
types, and a particular characteristic of papillomaviruses
is that partly overlapping ORFs are arranged on only
one DNA strand. The genome can be divided into three
regions. Two of these regions are the long control region
of early proteins (E1–E8), and the region of late proteins
(L1 and L2). The L1 and L2 structural proteins make up
the capsomeres; the 57-Kd L1 protein accounts for 80%
of the viral particle.
E6 and E7 are the most important oncogenic
proteins. Transcription of the E6 and E7 genes always
occurs in cervical carcinomas, and this discovery was
the first indication of an important role for these genes
in HPV-associated tumorigenesis [24,25]. The immor-
talizing and transforming potential of E6 and E7 proteins
has been demonstrated in numerous experiments, both
in tissue culture as well as experimental animal models
[26,27].
Cell-mediated Immune Responses in HPV
Infections and HPV-associated Neoplasms
The role of the immune response in limiting cervical
cancer development is unproven, but is supported
indirectly by the higher incidence of HPV infection,
cervical intraepithelial neoplasia (CIN), and disease
recurrence after treatment in immunocompromised
patients. HPV infection and cervical neoplasia are
associated with impaired cell-mediated immunity, not
disorders of humoral immunity, which implies that
cellular immune effectors are more important than
antibodies in these diseases.
Several lines of evidence suggest that cell-mediated
immune responses are important in controlling both
HPV infections and HPV-associated neoplasms [23].
First, the prevalence of HPV-related diseases (infections
and neoplasms) is increased in transplant recipients
[28] and patients with human immunodeficiency virus
(HIV) infection [29,30], both of whom are known to
have impaired cell-mediated immunity. Second, animal
studies have demonstrated that immunized animals are
protected from papillomavirus infection and from the
development of neoplasia. Immunization also facilitates
the regression of existing lesions [31–33]. Third,
infiltrating CD4+ T cells (T helper [Th] cells) and CD8+
T cells (cytotoxic/suppressor T cells) have been observed
in spontaneously regressing warts [34]. And finally,
warts in patients receiving immunosuppressive therapy
often disappear when this treatment is discontinued
[35].
The understanding of T-cell mediated immunity to
HPV infections was facilitated by identification of major
histocompatibility complex (MHC) class I and class II
epitopes of HPV proteins. Several groups have attempted
to map murine [36–38] and human [39–41] Th cell
epitopes as well as murine [42–48] and human [47–50]
cytotoxic T-lymphocyte (CTL) epitopes on HPV proteins.
Kast et al have identified several high-affinity binding
peptides of HPV-16 E6 and E7 proteins for human
histocompatibility leukocyte antigen (HLA)-A alleles
[48]. Moreover, HPV-specific CTLs recognizing HPV
E6 and E7 proteins have been demonstrated in the
peripheral blood of cervical cancer patients [51,52], in
healthy donors [40,49], and in patients with CIN lesions
[50,53,54]. Furthermore, infiltration of cervical cancer
tissue with HPV-specific CTLs has recently been described
[55]. Cell-mediated immune responses in HPV-infected
lesions can be demonstrated by in vitro CTL assays [52,
53,55] and in vitro lymphoproliferative response [41,
56–63].
Increasing evidence has suggested that inade-
quate antitumor responses can result from a failure of
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the helper arm of the immune response. The events
leading to the activation of CTL are tightly regulated
in order to protect against the development of inap-
propriate immune responses to self antigens or
exaggerated responses to foreign antigens. This regu-
lation is mediated by lymphokines produced by CD4+
T cells, which are critical to the generation of potent
antitumor immune responses and are instrumental
in generating immune responses against several solid
malignancies in mice [64] and humans [65,66]. Several
mouse tumors that are transfected with syngeneic MHC
class II genes become very effective vaccines against
subsequent challenge with wild-type class II-negative
tumors [67–69]. In addition, as crucial memory cells in
the T-cell arm of the immune system, CD4+ cells may be
able to provide long-term immunity against specific
antigens [70,71].
Any situation where there is a deficiency of cell-
mediated immunity will increase the likelihood of HPV
disease expression. Therefore, transplant recipients,
patients with diabetes mellitus or HIV, or those on
immunosuppressant drugs, such as steroids and
chemotherapy, are more likely to develop HPV disease
subsequent to HPV exposure [72]. Cigarette smoking
also reduces cell-mediated immunity, and there is a
correlation between smoking and malignant manifes-
tations of HPV disease [73].
Immune Escape
HPV infection is purely intraepithelial and has inherently
poor immunogenicity, possibly because of the poor
expression of co-stimulatory molecules (e.g. CD80),
and may not lead to appropriate immune activation in
peripheral lymphoid tissues. There are mechanisms by
which HPV lesions can evade immunosurveillance, such
as effector-cell dysfunction or tumor HLA loss. A number
of human cancers, such as prostate cancer [74] and
ovarian cancer [75], downregulate or lose HLA class I
molecules from the cell surface. HLA loss has been
reported in most cervical cancers and also in CIN, where
it acts as a marker of disease progression [76–81]. Since
HLA molecules are necessary for viral or tumor antigen
presentation to T lymphocytes, their loss has critical
implications for immune recognition. Peptide antigens
cannot be presented on the tumor cell surface, so the
lesion is not a target for specific CTLs and thus evades
cellular immunity. HLA loss may be a selective process
that enables cervical neoplasia to progress despite the
presence of immune effectors [82]. It may be possible
to upregulate HLA expression and render tumors sus-
ceptible to virus- or tumor-induced CTLs. Even in the
early stage of cervical neoplasia, HLA loss is caused by
a variety of mechanisms.
HPV Infection and Cervical Cancer
Infection with some mucosal types of HPV is now known
to precede cervical cancer development by several years.
Many studies have shown unequivocally that HPV DNA
can be detected in at least 99% of adequate cervical
cancer specimens, compared with 5–20% of cervical
specimens from women identified as suitable
epidemiologic controls [8,17,83]. HPV has been
recognized as a prerequisite for cervical cancer, and
certain types of HPV have now been designated as the
first ever identified necessary cause of a human cancer.
HPV infection is among the most common sexually
transmitted infections in most populations, and
estimates of exposure range from 15–20% in many
European countries to 70% in the USA and 95% in
high-risk populations in Africa [16].
Both the prevalence of HPV DNA in cervical cells and
the prevalence of cervical cancer in a population are
closely related to the age of subjects, although age
profiles differ. HPV infections are highly prevalent in
young individuals, whereas invasive cervical cancer does
not typically develop until the third decade of life or
later. Latent genital HPV infection can be detected in 5–
40% of sexually active women of reproductive age [2].
HPV prevalence is highest among young women soon
after the onset of sexual activity and falls gradually with
age until the fourth or fifth decade when, in some
populations, there is a second peak in prevalence
followed by another decline. Most HPV exposure occurs
soon after sexual initiation. Assessment of virgins after
their debut showed that exposure levels to HPV were
40% after 24 months and 70% by 56 months [84]. The
fact that prevalence falls rapidly after the peak in younger
ages probably reflects the accrued immunity that helps
to clear infections acquired after the onset of sexual
activity. The second age-specific prevalence peak may
reflect the loss of the original immunity against the HPV
types the women may have been exposed to in earlier
years or some form of cohort effect (variation in HPV
exposure for successive birth cohorts as they reach
adulthood). Most women who engage in sexual activity
will probably acquire HPV infection during their life-
time. The vast majority of these infections will clear
spontaneously to the point of no longer being detected,
even with sensitive assays. The concern is with long-term
persistent infections with high-risk (oncogenic) HPV
types, which substantially increase the risk of CIN and
cancer [17,85,86].
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The anogenital HPVs have been divided into two
groups: the high-risk HPVs (16, 18, 26, 31, 33, 35, 39,
45, 51, 52, 53, 56, 58, 59, 66, 68, 73 and 82) are
associated with a high risk for cervical cancer devel-
opment, and the low-risk HPVs (6, 11 ,40, 42, 43, 44,
54, 61, 72 and 81) with a low carcinogenic potential
[87]. It has now been proven that infection with a high-
risk HPV is a necessary prerequisite for the development
of cervical cancer, and the World Health Organization
(WHO) has recognized HPV-16 and HPV-18 as carcino-
genic agents in humans. The bulk of HPV infections
precede the bulk of cervical cancer by two to three
decades. However, follow-up studies are ethically
constrained to intervene at the stage of pre-invasive
disease (* CIN 2 in most settings), so the evolution of
the HPV infection to invasive cancer cannot be directly
assessed in prospective studies. Retrospective studies
on archival Papanicolaou (Pap) cervical smear samples
have successfully documented the existence of HPV
exposure decades before the development of the disease,
and have shown relative risk estimates for HPV positivity
and invasive cervical cancer of 16.4 and 32, respectively
[88].
HPV-related Cancer Preventive and
Therapeutic Vaccines
Cervical cancer represents a major disease burden
worldwide. Huge resources are spent on screening
women and managing those identified by abnormal
smears. Although effective treatment for early can-
cer exists, the mortality rate for advanced cervical
cancer exceeds 50% and there is a need for improved
adjuvant therapy. The situation in developing countries
is even more serious; national screening programs do
not exist, women frequently present with advanced
disease, and treatment facilities are limited. Most
treatments for anogenital warts prevent lesion prolifer-
ation or destroy or excise lesions without specifically
targeting the underlying HPV infection. Hence, the
potential for recurrence is high, and specific anti-
viral treatment or prophylaxis would be particularly
beneficial. CIN is now treated effectively and easily by
local excision or destruction, but there is still a degree
of morbidity associated with treatment procedures,
and the management of recurrent disease is more
complex.
These considerations illustrate the potentially
enormous health gain that would result from a prophy-
lactic vaccine to reduce the incidence of cervical can-
cer by preventing HPV infection, or from a therapeutic
vaccine for active treatment.
HPV as a Target in the Prevention of
Cervical Neoplasia
HPV infection is limited to the epithelium and the viral
lifecycle depends on infection of basal cells that normally
differentiate into mature squamous cells as they progress
towards the epithelial surface. HPV viral particles con-
sist of the viral DNA genome surrounded by the protein
capsid, which is composed of HPV L1 and L2 proteins.
Thus, it is possible that antibodies against L1 and L2
could be virus neutralizing and prevent or attenuate
infection. Once HPV infects, early viral proteins are
expressed within lower epithelial layers and viral rep-
lication occurs. As infected cells reach the surface, the
L1 and L2 proteins are produced and allow shedding of
mature virions with exfoliated cells. Cervical HPV
infection is usually benign, but its manifestations range
from “warty” epithelium with koilocytosis to overt
malignancy. During infection, HPV DNA is generally
found in the cytoplasm. However, most cervical tumors
show integration of high-risk HPV DNA into the host
genome, with loss of virion production (L1 and L2 are
not expressed). Integration commonly disrupts the HPV
virus to increase expression of E6 and E7 and then
convey a selective growth advantage. The effect of
integration is the transformation of infected cells into
a malignant phenotype. So, the constant presence of
E6 and E7 of high-risk HPV types could produce a thera-
peutic immune response.
A rational approach to the stimulation of anti-HPV
immunity requires knowledge of the immune response
in natural HPV infection. The type of response and its
mechanism, time-course and effects need to be deter-
mined. HPV causes no viremia or systemic manifesta-
tions, is non-cytolytic, and does not activate the in-
flammatory response. Such chronic infection is more
likely to result in immunologic tolerance than in acti-
vation. The ability of HPV to persist is consistent with
the concept of the virus having low immunogenicity.
However, there is almost certainly a role for the immune
system to limit and eradicate HPV infection.
Strategies for Vaccine Development
Approaches to vaccine development depend on whether
a prophylactic or therapeutic response is sought. The
targets of a prophylactic vaccine are L1 and L2 to induce
the humoral (antibody) responses, and the targets of a
therapeutic vaccine (immunotherapy) are E6 and E7 to
augment cellular (CTL) responses. Prophylaxis may occur
via virus-neutralizing antibodies to prevent HPV infection.
Specific serum immunoglobulin confers protection by
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exudation onto mucosal surfaces and inactivation of
the pathogen. For HPV, effective prophylactic
vaccination would generate antibodies in the genital
tract epithelium directed against the L1 and L2 capsid
proteins that have a role in viral entry. Prophylaxis may
be effective.
Immunotherapy for HPV infection or malignancy is
a more challenging target. Once cervical keratinocytes
have undergone transformation, they no longer express
HPV late genes and do not bind antibodies directed
against capsid proteins. Since continued expression of
E6 and E7 is necessary to maintain cells in a transformed
state, it is possible that the generation of specific CTLs
against high-risk HPV E6 and/or E7 peptides would lead
to the destruction of these infected tumor cells. These
concepts support the rationale for continued research
into HPV vaccines. Candidate HPV vaccines include
virus-like particles (VLPs), recombinant viral vectors,
recombinant bacterial vectors, viral DNA, proteins,
peptides, and dendritic cells.
Of these possible vehicles, recombinant viral vec-
tors have the advantage of inducing antibody responses
and stimulating specific CTLs. A vaccinia recombinant
vaccine was used in the first reported study of
HPV vaccination in humans [51]. It included HPV-16
and -18 E6 and E7 with modifications to minimize
oncogenicity. The ability of vaccinia to replicate in
human cells contributes to its immunogenicity and
efficiency as a viral vector. However, anti-vector immunity
limits the effectiveness of booster vaccinations. The
infectivity of vaccinia also increases its adverse-event
profile. Therefore, there is a place for vectors that can
infect human cells and express their genes, but which are
replication-deficient, such as DNA vaccines. DNA
vaccines are generally less potent than recombinants,
presumably because there is no replicative amplification
and less inflammation than attenuated infection [89–
91]. Their advantages include easy production, stability,
induction of both humoral and cellular responses, lack
of pathogenicity, and potential multivalency of a single
vaccine. HPV-16 E6, E7 and L1 plasmid DNA have been
used to generate both cell-mediated and antibody
responses, with tumor rejection or control.
Early vaccine studies have focused on HPV-16
antigens, due to the prevalence of HPV-16 in cancer and
the lack of diversity across types [92]. Vaccination
against low-risk HPV types would also be beneficial,
so further studies are indicated. However, the under-
standing of HPV population dynamics is far from
complete, and it cannot be assumed that vaccination
to eliminate infection by certain HPV types will not
alter infection rates and/or pathogenicity of other
types [93]. Evaluating the efficacy of HPV vaccines
can also be clinically problematic [94]. The influence
of age and sexual behavior on HPV acquisition should
be taken into account in order to define trial end
points. Other important factors are the latency of HPV
infection, because of its high clearance rate, the long
time-course from infection to development of CIN,
the frequency with which low-grade cervical lesions
regress, and uncertainty about the time taken for
CIN to become invasive. All these factors complicate
the design of clinical studies, where clinical end points
are required.
Choice of Population
In Phase I safety studies, trial populations often comprise
women with pre-existing infection [95,96]. However, if
a therapeutic vaccine became widely available, it would
need to be as effective as existing therapies before being
considered for the treatment of CIN. It is possible that
vaccination at the time of local treatment might reduce
recurrence of CIN. However, since recurrence is already
low, very large studies would be required to acquire
supportive evidence. Vaccination is unlikely to ever
become a primary treatment for cervical cancer, but
may prove to be beneficial as adjuvant therapy. The
place of prophylaxis remains equally uncertain and
raises the following questions. First, should vaccination
be offered to sexually active women, to young girls
before HPV exposure, or to all individuals for the devel-
opment of “herd” immunity? The answer will depend
on epidemiologic factors, a fuller understanding of the
natural history of HPV infection, and results obtained
from large-scale studies.
Development of Prophylactic and
Therapeutic Vaccines
When producing HPV vaccines, scientists normally
employ VLPs. These are empty virus capsids containing
the major HPV capsid antigen and, possibly, the minor
capsid antigens, but lack viral DNA. In order to obtain
such vaccines, DNA constructs encoding L1 or L1 and
L2 ORFs are transfected into eukaryotic cells, which
then produce these proteins. The proteins self-assemble
into VLPs, and a further purification step is undertaken
to confirm the existence of the VLPs, which are highly
immunogenic. The proper folding of the L1 or L2 proteins
is essential for vaccine development, as neutralization
epitopes are sensitive to conformation. Due to the high
level of antigenic specificity exhibited by the HPV capsid
antigens, no cross-protection among the HPV types has
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been observed. Therefore, vaccines need to be developed
for each HPV type.
Currently, vaccines directed against HPV-6, -11, -16
and -18 are in Phase III clinical trials; Phase I and II
studies have been reported [95–99]. Early studies have
shown that vaccination with VLPs is well tolerated and
induces a high-fold increase in titer, in terms of both
binding and neutralizing antibodies [100,101]. VLP
vaccines can also induce T-cell responses [102]. Koutsky
et al reported remarkable clinical findings using a VLP
vaccine against HPV-16 in young female volunteers
[99]. There was no HPV infection in the vaccinated
group, whereas 29 cases of persistent HPV-16 infection
were found in the placebo group. These results provide
strong evidence that type-specific VLPs can offer
protection from HPV infection and, thus, from cervical
cancer.
In addition, in order to obtain more effective HPV
VLP vaccines, scientists have attempted to construct
chimeric VLPs. Several additional approaches for
inducing cellular immunity, besides humoral immunity,
were attempted using chimeric VLPs. For example,
investigators have tried to link a segment of the gene
for E7 to the carboxyl terminus of L1 or L2 [103,104].
These chimeric VLP vaccines were found to boost both
humoral immunity to the VLP and cellular immunity
to L1 and E7.
The major limitation of the VLP vaccines is that they
are restricted to specific HPV types. Therefore, scientists
have attempted to construct vaccines that are cross-
reactive with other types of HPV. One approach employs
a denatured L1 protein, but the results indicated that
denatured VLPs are insufficient to generate neutralizing
antibodies [105,106]. Recent studies have reported
that denatured L2 protein can generate antibodies that
neutralize both homologous and heterologous HPV
types [107]. However, it is unclear whether the neutra-
lizing antibodies against the denatured L2 protein
are effective in preventing natural infections, as most
neutralizing antibodies appear to recognize the L1
protein.
Various attempts to develop DNA vaccines are
currently in progress. The production of a DNA vaccine
is relatively easy, and such vaccines tend to be effective
in the generation of both humoral and cellular pro-
tective immunity responses. However, a trial using an L1
DNA vaccine showed only weak immune responses to
HPV, due to the different codons of the viral L1 gene
used [108]. Recently, a codon-modified version of
a DNA vaccine targeting HPV-6 L1 and L1-E7 was
constructed and tested, to determine whether this
DNA vaccine would elicit an immune response in mice
[109]. Chimeric DNA vaccines targeting E7 have been
reported to provide both preventive and therapeutic
effects in mice [89,91,110–114]. Other clinical trials of
therapeutic vaccines such as a fusion protein [115,
116], dendritic cells [117], and a peptide [118] have
also demonstrated the induction of immune responses.
It will be interesting to observe the clinical results of
the trials of various strategies for therapeutic vaccines
in humans.
New strategies to prevent and treat HPV-related
cervical cancer are important in Taiwan. Important
criteria need to be met for the effective eradication of
cervical cancer. First, unique types of HPV should be
identified in Taiwanese women. These types may be
clearly distinct from the HPV types of other countries,
particularly the USA and Western countries. As HPV
vaccines limited to a few strains can be adapted to
generate new vaccines, a Taiwanese-type vaccine needs
to be developed. Second, efforts to support all immune
reactions need to be carried out. An appropriate meth-
od, which may involve cell therapy, DNA vaccines, or
recombinant DNA technology, needs to be developed
if HPV infection is to be prevented. Not only humoral
immunity, but also cellular immunity must be part of
this process. Third, immunosuppression in the late
stages of cervical cancer needs to be considered. There-
fore, combinatorial therapies would be much more
beneficial to women, with regard to boosting immune
response with the development of Taiwanese-style HPV
vaccines.
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